Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769167 | 1.00 | MAPK1 (0.65) | MAPK1L3MBTL1KDM4EMAOBPTK2 | |
| SCHEMBL5937430 | 0.86 | EGLN1 (0.57) | MAPK1L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL24512735 | 0.83 | P2RX3 (0.56) | MAPK1L3MBTL1KDM4E | |
| SCHEMBL14003355 | 0.82 | MAOB (0.49) | MAPK1L3MBTL1MAOBPTK2TRPA1 | |
| SCHEMBL28937138 | 0.82 | HTR1F (0.58) | L3MBTL1KDM4EALDH1A1MRGPRX4 | |
| SCHEMBL31235495 | 0.80 | CYP1A2 (0.51) | KDM4EMAOBALDH1A1 | |
| SCHEMBL2414269 | 0.80 | CYP1A2 (0.51) | KDM4EMAOBALDH1A1 | |
| SCHEMBL12474883 | 0.80 | TRPA1 (0.57) | MAPK1MAOBPTK2TRPA1 | |
| SCHEMBL14234693 | 0.80 | MAPK1 (0.80) | MAPK1L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL31312576 | 0.79 | MAOB (0.50) | MAPK1L3MBTL1MAOBPTK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739685-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025008061-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |